Drug Discovery 서비스 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Drug Discovery Services Market was valued at USD 19.2 billion in 2025 and is estimated to grow at a CAGR of 13.5% to reach USD 67.3 billion by 2035.

The market is experiencing expansion as pharmaceutical and biotechnology companies increasingly rely on external research partners to improve discovery efficiency, reduce development timelines, and optimize research investments. The growing complexity of modern drug development, increasing adoption of advanced computational approaches, and rising demand for innovative therapies are accelerating the use of specialized drug discovery service providers. A major factor shaping future growth is the transition toward strategic outsourcing, where companies are forming long-term collaborations with contract research organizations (CROs) to access advanced capabilities and flexible research models. The rising presence of biologics in development pipelines and the growing application of artificial intelligence across discovery workflows are further enhancing market opportunities. AI-based platforms are improving efficiency in areas such as target identification, molecule screening, and candidate assessment, helping researchers make faster and more informed decisions. Continued pharmaceutical R&D investment, with global spending exceeding USD 250 billion annually, is supporting demand for outsourced discovery solutions as companies seek greater speed, scalability, and cost control throughout the innovation process.

The target selection segment held a 10.3% share in 2025, highlighting its importance as an early-stage activity that influences the overall success of drug development programs. This segment focuses on identifying and evaluating biological targets that can potentially deliver therapeutic benefits for specific medical conditions. Advancements in computational biology, data analytics, and AI-enabled research platforms have expanded the ability of scientists to explore new therapeutic opportunities and improve target validation processes.

The pharmaceutical and biotechnology segment held a 68.8% share in 2025. The strong position of this segment is supported by the increasing dependence of drug developers on outsourced research services to enhance internal capabilities, accelerate discovery timelines, and manage operational costs. CRO partnerships allow companies to access specialized expertise and advanced technologies while maintaining flexibility throughout research programs.

North America Drug Discovery Services Market held a 45.56% share in 2025. The region's leadership is supported by the strong presence of pharmaceutical and biotechnology companies, advanced research infrastructure, significant investment in life sciences innovation, and a regulatory framework that supports advanced drug discovery and development activities.

Major players operating in the global drug discovery services market are WuXi AppTec Co., Ltd.; Charles River Laboratories International, Inc.; Evotec SE; Pharmaron Beijing Co., Ltd.; Thermo Fisher Scientific Inc. (PPD); Eurofins Scientific SE; Labcorp Drug Development; Syngene International Limited; Curia Global, Inc.; BioDuro-Sundia; Sai Life Sciences Limited; Selvita S.A.; Aragen Life Sciences Ltd.; Aurigene Pharmaceutical Services Ltd.; and Sygnature Discovery Ltd. Key strategies adopted by companies in the drug discovery services market include expanding service portfolios, investing in AI-driven research platforms, strengthening technology capabilities, and building strategic partnerships with pharmaceutical and biotechnology firms. Leading providers are focusing on integrated discovery solutions that cover multiple stages of research to improve customer retention and create long-term collaborations. Companies are also increasing investments in automation, advanced analytics, and specialized scientific expertise to enhance efficiency and deliver faster outcomes.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
  • 2.1.1 Business trends
  • 2.1.2 Process trends
  • 2.1.3 Type trends
  • 2.1.4 Drug type trends
  • 2.1.5 Therapeutic area trends
  • 2.1.6 End use trends
  • 2.1.7 Regional trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing R&D expenditure
    • 3.2.1.2 Rising prevalence of chronic diseases
    • 3.2.1.3 Rising demand for novel therapeutic drugs
    • 3.2.1.4 Growth in precision medicine and targeted therapies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulations governing drug discovery
    • 3.2.2.2 High attrition rates in drug development
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration of AI and digital technologies in drug discovery
    • 3.2.3.2 Expansion of outsourcing to emerging markets
• 3.3 Growth potential analysis
• 3.4 Technology and innovation landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Pricing trend analysis (Driven by primary research)
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 MEA
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Patent analysis
• 3.10 Future market trends
• 3.11 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.12 Investment & funding analysis (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Process, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Target selection
• 5.3 Target validation
• 5.4 Hit-to-lead identification
• 5.5 Lead optimization
• 5.6 Candidate validation

Chapter 6 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Chemistry services
• 6.3 Biological services

Chapter 7 Market Estimates and Forecast, By Drug Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Small-molecule drugs
• 7.3 Large-molecule drugs

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Diabetes
• 8.3 Neurology
• 8.4 Oncology
• 8.5 Infectious diseases
• 8.6 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical & biotechnology companies
• 9.3 Contract Research Organizations
• 9.4 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 UK
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Charles River Laboratories International, Inc.
• 11.2 WuXi AppTec Co., Ltd.
• 11.3 Pharmaron Beijing Co., Ltd.
• 11.4 Labcorp Drug Development
• 11.5 Evotec SE
• 11.6 Thermo Fisher Scientific Inc.
• 11.7 Eurofins Scientific SE
• 11.8 Syngene International Limited
• 11.9 Curia Global, Inc.
• 11.10 Sai Life Sciences Limited
• 11.11 Aragen Life Sciences Ltd.
• 11.12 Sygnature Discovery Ltd.
• 11.13 BioDuro-Sundia
• 11.14 Aurigene Pharmaceutical Services Ltd.
• 11.15 Selvita S.A.